Payment of 2707 shares by Charles Wagner of Vertex Pharmaceuticals subject to Rule 16b-3
VX1 Stock | EUR 375.00 9.50 2.47% |
Roughly 62% of Vertex Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Vertex Pharmaceuticals Incorporated suggests that many traders are alarmed regarding Vertex Pharmaceuticals' prospects. The current market sentiment, together with Vertex Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Vertex Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Vertex Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Vertex daily returns and investor perception about the current price of Vertex Pharmaceuticals Incorporated as well as its diversification or hedging effects on your existing portfolios.
Vertex |
Filed transaction by Vertex Pharmaceuticals In officer. Payment of exercise price or tax liability by delivering or withholding securities
Read at macroaxis.com
Vertex Pharmaceuticals Fundamental Analysis
We analyze Vertex Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vertex Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vertex Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Vertex Pharmaceuticals is rated fifth in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Vertex Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vertex Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Vertex Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Vertex Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Vertex Pharmaceuticals Related Equities
NOVA | Novo Nordisk | 23.88 | ||||
0QF | Moderna | 4.41 | ||||
1FW1 | WUXI BIOLOGICS | 1.95 | ||||
CSJA | CSL | 0.61 | ||||
MBG | Mercedes Benz | 0.30 | ||||
22UA | BioNTech | 0.46 | ||||
CSJ | CSL | 0.60 | ||||
VX1 | Vertex Pharmaceuticals | 2.47 |
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |